title: Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone.
abstract: A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.
authors.affiliation: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Hiyamuta
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Yamada
authors.forename: Yuta
authors.initials: Y
authors.lastname: Matsukuma
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tsuchimoto
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Nakano
authors.forename: Masatomo
authors.initials: M
authors.lastname: Taniguchi
authors.forename: Kosuke
authors.initials: K
authors.lastname: Masutani
authors.forename: Goichi
authors.initials: G
authors.lastname: Yoshimoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Muta
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
authors.forename: Takanari
authors.initials: T
authors.lastname: Kitazono
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Tsuruya
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008558:Melphalan / Q000008:administration & dosage; D010265:Paraproteinemias / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000069286:Bortezomib; D008558:Melphalan; D011241:Prednisone